Drug intelligence / Profile preview

amoxicillin + clarithromycin + lansoprazole + metronidazole

Development stage
Unknown
Lead developer
Takeda
Modality
Small Molecules
Administration
Oral
01

Overview

This combination is a type of concomitant therapy used for Helicobacter pylori (H. pylori) eradication. It consists of amoxicillin (a penicillin antibiotic), clarithromycin (a macrolide antibiotic), metronidazole (an antibiotic and antiprotozoal), and lansoprazole (a proton pump inhibitor). The antibiotics work by killing bacteria or preventing their growth, while lansoprazole decreases stomach acid production, creating a less acidic environment that weakens H. pylori bacteria and allows the antibiotics to work more effectively. This four-drug regimen is particularly useful in areas with high resistance to clarithromycin or metronidazole, as the combination helps overcome resistance to individual antibiotics.

Other names
Concomitant therapy
02

Targets

PBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)CYP3A4 (Cytochrome P450 3A4)Neuraminidase23S rRNA (23S ribosomal RNA)

Beyond the preview

Go deeper on amoxicillin + clarithromycin + lansoprazole + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amoxicillin + clarithromycin + lansoprazole + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call